Biosimilars | Market Events and Forecast Landscape – Overview of Biosimilar Forecasts | 2022
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in these therapy areas totaled approximately $15 billion. Throughout our 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
